After unseating Harvard, MIT is this year’s dream school, according to a new survey of college-bound students.
Related Posts
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
Trump was supposed to unlock IPO market, but CoreWeave debut reflects ongoing skepticism
After pricing its IPO below the expected range, CoreWeave’s stock didn’t do much in its debut on Friday, reflecting concerns about the macro environment.
Lucid slightly tops Wall Street’s third-quarter expectations amid widening losses
The company’s net loss for the third quarter widened to $992.5 million compared to a loss of $630.9 million a year earlier.